Dynamic Resilience

Dynamic Resilience — Execution

Funds healthspan-oriented research in the United Kingdom toward resilient aging and wellness strategies.

Dynamic Resilience is a $60 million program co-funded by Wellcome Leap and Temasek Trust, a Singapore-based philanthropic organization, aimed at identifying and validating causal measures of health resilience across biological scales. The program is directed by Lynne Cox, PhD, Associate Professor of Biochemistry at the University of Oxford and a specialist in biological aging and cell senescence. Dynamic Resilience pursues three technical objectives: identifying multimodal biomarker signatures of resilience predictive of health outcomes following stress events, elucidating the underlying mechanisms of frailty and resilience through human-centric laboratory and computational models, and conducting proof-of-concept studies and clinical trials targeting a reduction of at least 25 percent in frailty progression.

Performer teams have been selected and are executing on resilience biomarker studies and clinical trials. No open solicitation was active at the time of research. Wellcome Leap programs generally accept applications from universities, nonprofits, for-profit organizations, and research institutes; individual applicants are not eligible. Award sizes per team are not publicly disclosed; the total investment is $60 million shared between Wellcome Leap and Temasek Trust. The cooperative-agreement model requires performers to meet milestone-based accountability standards set by Wellcome Leap rather than self-directing research.

For organizations working in longitudinal aging cohorts, wearable biosensors, frailty assessment, or cellular senescence, Dynamic Resilience defines the active funding frontier in healthspan science. The co-funding structure with Temasek Trust suggests an interest in research with applicability to Asian populations and global health systems. Organizations seeking future engagement should monitor wellcomeleap.org/dr and be prepared to demonstrate not just scientific quality but concrete measurability: the 25 percent frailty-reduction target reflects Wellcome Leap's standard practice of setting quantified success criteria.